Chiron to distribute Cardiovascular tests:
This article was originally published in Clinica
Chiron Diagnostics will take on worldwide distribution of Cardiovascular Diagnostics' near-patient coagulation tests. In the US, Chiron will start distribution in January 1999, as Cardiovascular's current marketing agreements, with Dade Behring and Avecor Cardiovascular, expire. Chiron will launch the tests separately, as well as incorporating them onto its Rapidpoint 400 critical care system, set for a launch this year. According to Chiron, the coagulation products are part of its strategy to "redefine our critical care product portfolio". Chiron will also invest $6 million in Cardiovascular stock.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.